이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Alibaba Health Information Technology 관리
관리 기준 확인 2/4
Alibaba Health Information Technology's CEO는 Difan Shen, Nov2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 CN¥ 6.41M, 23% 로 구성됩니다. 23% 급여 및 77% 보너스(회사 주식 및 옵션 포함). 는 HK$ 4.17M 가치에 해당하는 회사 주식의 0.007% 직접 소유합니다. 4.17M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 1.9 년입니다.
주요 정보
Difan Shen
최고 경영자
CN¥6.4m
총 보상
| CEO 급여 비율 | 23.0% |
| CEO 임기 | less than a year |
| CEO 소유권 | 0.009% |
| 경영진 평균 재임 기간 | 1.9yrs |
| 이사회 평균 재임 기간 | 2yrs |
최근 관리 업데이트
Recent updates
After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07
Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥883m |
| Dec 31 2023 | n/a | n/a | CN¥850m |
| Sep 30 2023 | n/a | n/a | CN¥817m |
| Jun 30 2023 | n/a | n/a | CN¥675m |
| Mar 31 2023 | CN¥6m | CN¥1m | CN¥533m |
| Dec 31 2022 | n/a | n/a | CN¥332m |
| Sep 30 2022 | n/a | n/a | CN¥128m |
| Jun 30 2022 | n/a | n/a | -CN¥69m |
| Mar 31 2022 | CN¥6m | CN¥1m | -CN¥266m |
| Dec 31 2021 | n/a | n/a | -CN¥216m |
| Sep 30 2021 | n/a | n/a | -CN¥167m |
| Jun 30 2021 | n/a | n/a | CN¥91m |
| Mar 31 2021 | n/a | n/a | CN¥349m |
| Dec 31 2020 | n/a | n/a | CN¥313m |
| Sep 30 2020 | n/a | n/a | CN¥278m |
| Jun 30 2020 | n/a | n/a | CN¥136m |
| Mar 31 2020 | CN¥12m | CN¥2m | -CN¥7m |
| Dec 31 2019 | n/a | n/a | -CN¥3m |
| Sep 30 2019 | n/a | n/a | CN¥1m |
| Jun 30 2019 | n/a | n/a | -CN¥40m |
| Mar 31 2019 | CN¥7m | CN¥33k | -CN¥82m |
보상 대 시장: Difan 의 총 보상 ($USD 882.37K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 886.33K ).
보상과 수익: Difan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Difan Shen (46 yo)
less than a year
테뉴어
CN¥6,406,000
보상
Mr. Difan Shen serves as Chief Executive Officer of Alibaba Health Information Technology Limited from November 28, 2023 and serves as Executive Director since October 13, 2021. He was Chief Operating Offi...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board | 4.3yrs | CN¥11.33m | 0.0086% CN¥ 4.3m | |
| CEO & Executive Director | less than a year | CN¥6.41m | 0.0089% CN¥ 4.5m | |
| CFO & Executive Director | 4.3yrs | CN¥3.24m | 0.0050% CN¥ 2.5m | |
| Legal Counsel & Joint Company Secretary | 1.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Marketing Officer | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 4.4yrs | 데이터 없음 | 데이터 없음 | |
| Financial Controller | no data | 데이터 없음 | 데이터 없음 | |
| Chief Legal Advisor & Joint Company Secretary | less than a year | 데이터 없음 | 데이터 없음 |
1.9yrs
평균 재임 기간
46yo
평균 연령
경험이 풍부한 관리: 241 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board | 4.3yrs | CN¥11.33m | 0.0086% CN¥ 4.3m | |
| CEO & Executive Director | 2.8yrs | CN¥6.41m | 0.0089% CN¥ 4.5m | |
| CFO & Executive Director | 3.8yrs | CN¥3.24m | 0.0050% CN¥ 2.5m | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 5.1yrs | CN¥330.00k | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
2.0yrs
평균 재임 기간
48yo
평균 연령
경험이 풍부한 이사회: 241 의 이사회는 경험(평균 재직 기간 1.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.